1. Home
  2. EVGO vs CLLS Comparison

EVGO vs CLLS Comparison

Compare EVGO & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EVgo Inc.

EVGO

EVgo Inc.

N/A

Current Price

$2.10

Market Cap

308.9M

ML Signal

N/A

Logo Cellectis S.A.

CLLS

Cellectis S.A.

N/A

Current Price

$3.33

Market Cap

384.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EVGO
CLLS
Founded
2010
1999
Country
United States
France
Employees
331
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
308.9M
384.3M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
EVGO
CLLS
Price
$2.10
$3.33
Analyst Decision
Buy
Strong Buy
Analyst Count
8
2
Target Price
$5.20
$8.50
AVG Volume (30 Days)
3.8M
35.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$26.07
$40.37
Revenue Next Year
$26.76
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.07
$1.10
52 Week High
$5.18
$5.48

Technical Indicators

Market Signals
Indicator
EVGO
CLLS
Relative Strength Index (RSI) 26.61 37.85
Support Level N/A $3.12
Resistance Level $3.27 $3.77
Average True Range (ATR) 0.17 0.19
MACD -0.05 -0.02
Stochastic Oscillator 4.64 5.82

Price Performance

Historical Comparison
EVGO
CLLS

About EVGO EVgo Inc.

EVgo owns and operates a public direct current fast-charging network in the US. Its network of charging stations provides electric vehicle charging infrastructure to consumers and businesses. The network is capable of charging all EV models and meets all charging standards currently available in the US. EVgo partners with national and regional chains of grocery stores, automotive original equipment manufacturers, hotels, shopping centers, gas stations, parking lot operators, local governments, and independent property owners to locate and deploy its EV charging infrastructure.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: